EVGN
Evogene Ltd.
There isn't enough reported data to score EVGN yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EVGN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
EVGN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EVGN PE Valuation
EVGN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EVGN Forward outlook
There aren't enough analyst estimates for EVGN to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EVGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.91 | +$1.34 |
| Q1 2026 | -$1.39 | +$1.30 |
| Q4 2025 | -$1.17 | +$1.90 |
| Q3 2025 | -$0.50 | +$3.93 |
| Q2 2025 | -$2.25 | +$1.68 |
| Q1 2025 | -$2.69 | +$1.73 |
| Q4 2024 | -$3.07 | +$2.10 |
EVGN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EVGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $347K | -61% |
| Q1 2026 | $334K | -86% |
| Q4 2025 | $314K | -81% |
| Q3 2025 | $312K | -82% |
| Q2 2025 | $884K | +46% |
| Q1 2025 | $2.4M | -42% |
| Q4 2024 | $1.6M | +179% |
| Q3 2024 | $1.7M | -54% |
EVGN's revenue has slid since its 2024 peak: $347,000 last quarter, down 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -703% | -356 points |
| Q1 2026 | -943% | -774 points |
| Q4 2025 | -1660% | -1376 points |
| Q3 2025 | -873% | -533 points |
| Q2 2025 | -347% | +418 points |
| Q1 2025 | -169% | -71 points |
| Q4 2024 | -283% | +1036 points |
| Q3 2024 | -340% | -229 points |
EVGN's operating margin was −703% last quarter, down 356 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EVGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over EVGN on profitability, with a higher operating margin.
EVGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.1M | +$224K |
| Q1 2026 | -$3M | +$2.3M |
| Q4 2025 | -$2.7M | +$2.8M |
| Q3 2025 | -$3.8M | +$1.3M |
| Q2 2025 | -$2.3M | +$3.1M |
| Q1 2025 | -$5.3M | -$1.1M |
| Q4 2024 | -$5.5M | +$482K |
| Q3 2024 | -$5.1M | -$527K |
EVGN has burned cash in almost every quarter: −$12M over the past year, against −$18M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EVGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
EVGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +2.5M shares |
| 1 year | +69% | +5M shares |
| 3 years | +170% | +7.7M shares |
EVGN has 12M diluted shares, up 69% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
EVGN hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EVGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EVGN Net Leverage
EVGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EVGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 10.1 | Oversold |
EVGN's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EVGN PE vs Healthcare Sector
EVGN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EVGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.37 | 2.7% below |
| 20 week MA | $0.47 | 23% below |
| 50 week MA | $0.70 | 49% below |
| 100 week MA | $1.00 | 64% below |
| 200 week MA | $3.71 | 90% below |
EVGN is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EVGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.6 | $44.1 | +183% |
| 2021 | $44.1 | $17.1 | -61% |
| 2022 | $17.1 | $7.59 | -56% |
| 2023 | $7.59 | $8.40 | +11% |
| 2024 | $8.40 | $1.65 | -80% |
| 2025 | $1.65 | $1.03 | -38% |
| 2026 YTD | $1.03 | $0.36 | -65% |
EVGN's yearly returns have swung widely, from +183% in 2020 to −80% in 2024. It's down 65% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EVGN on returns for 2026, with the stronger performance.